PHASQ
Price:
$0.000001
Market Cap:
$0
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd...[Read more]
Industry
Biotechnology
IPO Date
2018-10-18
Stock Exchange
PNK
Ticker
PHASQ
According to PhaseBio Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.00. This represents a change of -100.00% compared to the average of -0.67 of the last 4 quarters.
The mean historical PE Ratio of PhaseBio Pharmaceuticals, Inc. over the last ten years is -100.59. The current -0.00 PE Ratio has changed -100.00% with respect to the historical average. Over the past ten years (40 quarters), PHASQ's PE Ratio was at its highest in in the December 2021 quarter at 0.36. The PE Ratio was at its lowest in in the June 2019 quarter at -10.50.
Average
-100.59
Median
-4.89
Minimum
-585.39
Maximum
-0.69
Discovering the peaks and valleys of PhaseBio Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 59.00%
Maximum Annual PE Ratio = -0.69
Minimum Annual Increase = -87.48%
Minimum Annual PE Ratio = -585.39
Year | PE Ratio | Change |
---|---|---|
2021 | -585.39 | 59.00% |
2020 | -0.99 | -76.86% |
2019 | -4.28 | 522.63% |
2018 | -0.69 | -87.48% |
2017 | -5.49 | -18.31% |
The current PE Ratio of PhaseBio Pharmaceuticals, Inc. (PHASQ) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-196.89
5-year avg
-119.37
10-year avg
-100.59
PhaseBio Pharmaceuticals, Inc.’s PE Ratio is greater than Ceapro Inc. (-2.83), greater than Oncotelic Therapeutics, Inc. (-2.62), greater than Processa Pharmaceuticals, Inc. (-0.25), less than Kaleido Biosciences, Inc. (0),
Company | PE Ratio | Market cap |
---|---|---|
-2.83 | $13.31M | |
-2.62 | $12.22M | |
-0.25 | $2.85M | |
0 | $4.26K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like PhaseBio Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like PhaseBio Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is PhaseBio Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
What is the highest PE Ratio for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
What is the 3-year average PE Ratio for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
What is the 5-year average PE Ratio for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
How does the current PE Ratio for PhaseBio Pharmaceuticals, Inc. (PHASQ) compare to its historical average?